Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
21 Octobre 2022 - 2:00PM
NightHawk Biosciences (NYSE American: NHWK),
a fully integrated biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system, today
announced that its Scorpion subsidiary plans to host the grand
opening of its San Antonio facility today, October 21.
David Halverson, President of Scorpion,
commented, “We are pleased with the recent FDA feedback regarding
our design, operational strategy, and environmental controls
relevant to clinical and commercial manufacturing at our San
Antonio facility. In addition, the planning for our new facility in
Manhattan, Kansas continues to progress. These two facilities, once
fully operational, will provide Scorpion with substantial
biomanufacturing capabilities to accommodate future worldwide
demand for biologic manufacturing.”
The global pharmaceutical CDMO market is
projected to reach $171 billion by 2026 from $120 billion in 20211.
The industry currently suffers from a significant lack of capacity,
resulting in meaningful delays and escalating costs.
The Company also reports its Scorpion subsidiary
recently entered into a commercial contract to provide contract
development and manufacturing services for a biopharmaceutical
company to support development of their Phase 3 asset.
Jeff Wolf, CEO of Nighthawk, further noted, “We
look forward to hosting the formal grand opening of our Scorpion
San Antonio facility which represents an important milestone for
the Company as we continue to execute on our strategy to develop a
fully-integrated ecosystem that is designed to enable more rapid
delivery of medical innovations with increased quality and
efficiency.”
About Scorpion Biological
ServicesScorpion Biological Services is a contract
research, and contract development and manufacturing organization
(CDMO) focused on cell- and gene-based therapies and large molecule
biologics. Scorpion provides a broad array of clinical-scale
biomanufacturing, analytical and R&D services to pharmaceutical
and biotech companies from its San Antonio, Texas facilities.
Scorpion also plans to offer commercial-scale biomanufacturing from
its newly announced site in Manhattan, Kansas. Additional
information is available at: https://www.scorpionbio.com/.
NightHawk Biosciences,
Inc.NightHawk Biosciences is a fully integrated
biopharmaceutical company focused on the development of new drugs
from discovery through commercialization. The Company leverages its
integrated ecosystem of subsidiaries to accelerate the development
of novel therapies that arm the immune system, breaking through
barriers that prolong traditional drug development. This empowers
us to bring our ideas to life with efficient control, superior
quality, and uncharacteristic agility.
For more information on the Company and is
subsidiaries, please visit: www.nighthawkbio.com, and follow
us on Twitter.
Forward Looking StatementThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions, and include statements such as the Scorpion’s plans to
host the grand opening of its San Antonio facility on October 21,
planning for our new facility in Manhattan, Kansas continues to
progress, the two facilities, once fully operational, providing
Scorpion with substantial biomanufacturing capabilities to
accommodate future worldwide demand for biologic manufacturing the
global pharmaceutical CDMO market being projected to reach $171
billion by 2026 from $120 billion in 2021, and continuing to
execute on the Company’s strategy to develop a fully-integrated
ecosystem that is designed to enable more rapid delivery of medical
innovations with increased quality and efficiency. Important
factors that could cause actual results to differ materially from
current expectations include, among others, the ability to open the
San Antonio facility and Kansas facility when planned, the ability
of Scorpion to accommodate future worldwide demand for biologic
manufacturing the global pharmaceutical CDMO market, the size of
the global pharmaceutical CDMO market, the ability to develop a
fully-integrated ecosystem that is designed to enable more rapid
delivery of medical innovations with increased quality and
efficiency, , the ability of Scorpion to leverage its biologic
manufacturing capabilities, whether the combined business of
NightHawk and Elusys will be successful, NightHawk’s ability to
successfully operate as a CDMO, NightHawk’s and its subsidiaries’
ability to maintain license agreements, the continued maintenance
and growth of NightHawk’s and its subsidiaries’ patent estates,
NightHawk’s product candidates demonstrating safety and
effectiveness, as well as results that are consistent with prior
results, the ability to initiate clinical trials and if initiated,
the ability to complete them on time and achieve the desired
results and benefits continuing enrollment as expected, the ability
to obtain regulatory approval for commercialization of product
candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to NightHawk’s ability to promote
or commercialize its product candidates for the specific
indications, acceptance of product candidates in the marketplace
and the successful development, marketing or sale of NightHawk’s
products, developments by competitors that render such products
obsolete or non-competitive, and other factors described in
NightHawk’s annual report on Form 10-K for the year ended December
31, 2021, subsequent quarterly reports on Form 10-Qs and any other
filings NightHawk makes with the SEC. The information in this
presentation is provided only as of the date presented, and
NightHawk undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
_________________________
1
https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-contract-manufacturing-market-201524381.html?gclid=Cj0KCQjw_viWBhD8ARIsAH1mCd5GN2FB5wstsuUSbLcWUnl5ESygiO41tyZjJ3e990Qwh_uJsLC472gaAi89EALw_wcB
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024